200 related articles for article (PubMed ID: 30246417)
1. Design, Synthesis, and SAR Studies of Heteroarylpyrimidines and Heteroaryltriazines as CB
Qian HY; Wang ZL; Chen LL; Pan YL; Xie XY; Xie X; Chen JZ
ChemMedChem; 2018 Nov; 13(22):2455-2463. PubMed ID: 30246417
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, in vitro and in vivo evaluation of 1,3,5-triazines as cannabinoid CB2 receptor agonists.
Yrjölä S; Sarparanta M; Airaksinen AJ; Hytti M; Kauppinen A; Pasonen-Seppänen S; Adinolfi B; Nieri P; Manera C; Keinänen O; Poso A; Nevalainen TJ; Parkkari T
Eur J Pharm Sci; 2015 Jan; 67():85-96. PubMed ID: 25447744
[TBL] [Abstract][Full Text] [Related]
3. Design, syntheses, structure-activity relationships and docking studies of coumarin derivatives as novel selective ligands for the CB2 receptor.
Han S; Zhang FF; Qian HY; Chen LL; Pu JB; Xie X; Chen JZ
Eur J Med Chem; 2015 Mar; 93():16-32. PubMed ID: 25644673
[TBL] [Abstract][Full Text] [Related]
4. Developing pyridazine-3-carboxamides to be CB2 agonists: The design, synthesis, structure-activity relationships and docking studies.
Qian HY; Wang ZL; Xie XY; Pan YL; Li GJ; Xie X; Chen JZ
Eur J Med Chem; 2017 Sep; 137():598-611. PubMed ID: 28651225
[TBL] [Abstract][Full Text] [Related]
5. New Pyridone-Based Derivatives as Cannabinoid Receptor Type 2 Agonists.
Faúndez-Parraguez M; Alarcón-Miranda C; Cho YH; Pessoa-Mahana H; Gallardo-Garrido C; Chung H; Faúndez M; Pessoa-Mahana D
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681877
[TBL] [Abstract][Full Text] [Related]
6. Amidoalkylindoles as Potent and Selective Cannabinoid Type 2 Receptor Agonists with in Vivo Efficacy in a Mouse Model of Multiple Sclerosis.
Shi Y; Duan YH; Ji YY; Wang ZL; Wu YR; Gunosewoyo H; Xie XY; Chen JZ; Yang F; Li J; Tang J; Xie X; Yu LF
J Med Chem; 2017 Aug; 60(16):7067-7083. PubMed ID: 28726401
[TBL] [Abstract][Full Text] [Related]
7. Synthesis, Pharmacological Evaluation, and Docking Studies of Novel Pyridazinone-Based Cannabinoid Receptor Type 2 Ligands.
Ragusa G; Bencivenni S; Morales P; Callaway T; Hurst DP; Asproni B; Merighi S; Loriga G; Pinna GA; Reggio PH; Gessi S; Murineddu G
ChemMedChem; 2018 Jun; 13(11):1102-1114. PubMed ID: 29575721
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and SAR evaluation of coumarin derivatives as potent cannabinoid receptor agonists.
Mohr F; Hurrle T; Burggraaff L; Langer L; Bemelmans MP; Knab M; Nieger M; van Westen GJP; Heitman LH; Bräse S
Eur J Med Chem; 2021 Aug; 220():113354. PubMed ID: 33915369
[TBL] [Abstract][Full Text] [Related]
9. The discovery of a potent and selective pyrazolo-[2,3-e]-[1,2,4]-triazine cannabinoid type 2 receptor agonist.
Moir M; Lane S; Montgomery AP; Hibbs D; Connor M; Kassiou M
Eur J Med Chem; 2021 Jan; 210():113087. PubMed ID: 33321261
[TBL] [Abstract][Full Text] [Related]
10. Cannabinoid agonists showing BuChE inhibition as potential therapeutic agents for Alzheimer's disease.
González-Naranjo P; Pérez-Macias N; Campillo NE; Pérez C; Arán VJ; Girón R; Sánchez-Robles E; Martín MI; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Páez JA
Eur J Med Chem; 2014 Feb; 73():56-72. PubMed ID: 24378710
[TBL] [Abstract][Full Text] [Related]
11. Fenchone Derivatives as a Novel Class of CB2 Selective Ligands: Design, Synthesis, X-ray Structure and Therapeutic Potential.
Smoum R; Haj C; Hirsch S; Nemirovski A; Yekhtin Z; Bogoslavsky B; Bakshi GK; Chourasia M; Gallily R; Tam J; Mechoulam R
Molecules; 2022 Feb; 27(4):. PubMed ID: 35209170
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and biological evaluation of aminoalkylindole derivatives as cannabinoid receptor ligands with potential for treatment of alcohol abuse.
Vasiljevik T; Franks LN; Ford BM; Douglas JT; Prather PL; Fantegrossi WE; Prisinzano TE
J Med Chem; 2013 Jun; 56(11):4537-50. PubMed ID: 23631463
[TBL] [Abstract][Full Text] [Related]
13. 7-Alkyl-3-benzylcoumarins: a versatile scaffold for the development of potent and selective cannabinoid receptor agonists and antagonists.
Rempel V; Volz N; Hinz S; Karcz T; Meliciani I; Nieger M; Wenzel W; Bräse S; Müller CE
J Med Chem; 2012 Sep; 55(18):7967-77. PubMed ID: 22916707
[TBL] [Abstract][Full Text] [Related]
14. New pyridazinone-4-carboxamides as new cannabinoid receptor type-2 inverse agonists: Synthesis, pharmacological data and molecular docking.
Ragusa G; Gómez-Cañas M; Morales P; Rodríguez-Cueto C; Pazos MR; Asproni B; Cichero E; Fossa P; Pinna GA; Jagerovic N; Fernández-Ruiz J; Murineddu G
Eur J Med Chem; 2017 Feb; 127():398-412. PubMed ID: 28088085
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and structure activity relationship investigation of triazolo[1,5-a]pyrimidines as CB2 cannabinoid receptor inverse agonists.
Aghazadeh Tabrizi M; Baraldi PG; Ruggiero E; Saponaro G; Baraldi S; Poli G; Tuccinardi T; Ravani A; Vincenzi F; Borea PA; Varani K
Eur J Med Chem; 2016 May; 113():11-27. PubMed ID: 26922225
[TBL] [Abstract][Full Text] [Related]
16. Negative allosteric modulators of cannabinoid receptor 2: protein modeling, binding site identification and molecular dynamics simulations in the presence of an orthosteric agonist.
Pandey P; Roy KK; Doerksen RJ
J Biomol Struct Dyn; 2020 Jan; 38(1):32-47. PubMed ID: 30652534
[TBL] [Abstract][Full Text] [Related]
17. Cryo-EM Structure of the Human Cannabinoid Receptor CB2-G
Xing C; Zhuang Y; Xu TH; Feng Z; Zhou XE; Chen M; Wang L; Meng X; Xue Y; Wang J; Liu H; McGuire TF; Zhao G; Melcher K; Zhang C; Xu HE; Xie XQ
Cell; 2020 Feb; 180(4):645-654.e13. PubMed ID: 32004460
[TBL] [Abstract][Full Text] [Related]
18. Structure-affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist.
Brizzi A; Aiello F; Marini P; Cascio MG; Corelli F; Brizzi V; De Petrocellis L; Ligresti A; Luongo L; Lamponi S; Maione S; Pertwee RG; Di Marzo V
Bioorg Med Chem; 2014 Sep; 22(17):4770-83. PubMed ID: 25065940
[TBL] [Abstract][Full Text] [Related]
19. Structure-activity relationships of thiazole and benzothiazole derivatives as selective cannabinoid CB2 agonists with in vivo anti-inflammatory properties.
Ghonim AE; Ligresti A; Rabbito A; Mahmoud AM; Di Marzo V; Osman NA; Abadi AH
Eur J Med Chem; 2019 Oct; 180():154-170. PubMed ID: 31302448
[TBL] [Abstract][Full Text] [Related]
20. 7-Azaindolequinuclidinones (7-AIQD): A novel class of cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptor ligands.
Penthala NR; Shoeib A; Dachavaram SS; Cabanlong CV; Yang J; Zhan CG; Prather PL; Crooks PA
Bioorg Med Chem Lett; 2020 Nov; 30(22):127501. PubMed ID: 32882418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
